Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
IDF destroys regime's missile, sea mine production site in Yazd amid nationwide airstrikes - 2Lift Your Style: Famous Hairdos for Ladies
- 3This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 4South African army arrive in crime hotspots to help tackle gangs
- 56 Methods for further developing Rest Quality
- WHO suspends Gaza medical evacuations after contractor killed by Israeli troops
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- The Iran war’s energy security legacy
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Promising Speculation Bearings for Portfolio Development in 2024
- The Century Coupe Could Be Toyota’s Most Ambitious Car Since the LFA
- German official report: Teen social media ban faces legal hurdles
